2014
Local versus general anesthesia for transcatheter aortic valve implantation (TAVR) – systematic review and meta-analysis
Fröhlich GM, Lansky AJ, Webb J, Roffi M, Toggweiler S, Reinthaler M, Wang D, Hutchinson N, Wendler O, Hildick-Smith D, Meier P. Local versus general anesthesia for transcatheter aortic valve implantation (TAVR) – systematic review and meta-analysis. BMC Medicine 2014, 12: 41. PMID: 24612945, PMCID: PMC4022332, DOI: 10.1186/1741-7015-12-41.Peer-Reviewed Original ResearchConceptsShorter hospital stayGeneral anesthesiaHospital stayRelative riskProcedure timeSevere aortic valve stenosisTranscatheter aortic valve implantationResultsSeven observational studiesAcute kidney injuryProcedure-related mortalityPooled relative riskAortic valve implantationAortic valve stenosisShort-term outcomesShorter procedure timeRandom-effects modelKidney injuryValve implantationOverall mortalityValve stenosisRandomized trialsTransfemoral TAVRLocal anesthesiaTreatment optionsMyocardial infarction
2010
Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents A Pooled Analysis From the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials
Caixeta A, Lansky AJ, Serruys PW, Hermiller JB, Ruygrok P, Onuma Y, Gordon P, Yaqub M, Miquel-Hebert K, Veldhof S, Sood P, Su X, Jonnavithula L, Sudhir K, Stone GW, Investigators S. Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents A Pooled Analysis From the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials. JACC Cardiovascular Interventions 2010, 3: 1220-1228. PMID: 21232715, DOI: 10.1016/j.jcin.2010.07.017.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicAspirinClopidogrelConfidence IntervalsCoronary Artery DiseaseDrug-Eluting StentsEverolimusFemaleFollow-Up StudiesHumansImmunosuppressive AgentsKaplan-Meier EstimateLogistic ModelsMaleMiddle AgedPaclitaxelPlatelet Aggregation InhibitorsProportional Hazards ModelsRandomized Controlled Trials as TopicRiskRisk Reduction BehaviorSirolimusTiclopidineTime FactorsConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsAdverse cardiac eventsTarget vessel failureCardiac eventsMyocardial infarctionSPIRIT IIProbable stent thrombosisAcademic Research ConsortiumEverolimus-eluting stentsVessel failureSignificant reductionLesion revascularizationPES patientsRevascularization eventsIII trialsClinical outcomesEE patientsStent thrombosisPooled analysisCumulative ratePersistent reductionSPIRIT IIIPatientsStents
2009
Paclitaxel-Eluting Stents versus Bare-Metal Stents in Acute Myocardial Infarction
Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Ochala A, Kellock A, Parise H, Mehran R. Paclitaxel-Eluting Stents versus Bare-Metal Stents in Acute Myocardial Infarction. New England Journal Of Medicine 2009, 360: 1946-1959. PMID: 19420364, DOI: 10.1056/nejmoa0810116.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryCombined Modality TherapyCoronary AngiographyCoronary RestenosisCoronary StenosisDrug-Eluting StentsFemaleFibrinolytic AgentsFollow-Up StudiesHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelRecurrenceRetreatmentRiskStentsSwedenConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionPaclitaxel-eluting stentsBare metal stentsElevation myocardial infarctionTarget lesion revascularizationMyocardial infarctionAngiographic evidenceEnd pointStent thrombosisIschemia-driven target lesion revascularizationPrimary PCIComposite safety end pointIdentical bare-metal stentMajor secondary end pointPrimary end pointSafety end pointSecondary end pointsTarget vessel revascularizationPercutaneous coronary interventionRepeat revascularization proceduresAcute myocardial infarctionSafety outcome measuresDrug-eluting stentsBinary restenosis
2008
A Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease Primary Results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II Study
Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ, Fitzgerald PJ, Garg J, Turco MA, Simonton CA, Verheye S, Dubois CL, Gammon R, Batchelor WB, O'Shaughnessy CD, Hermiller JB, Schofer J, Buchbinder M, Wijns W, Group C. A Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease Primary Results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II Study. Journal Of The American College Of Cardiology 2008, 51: 1543-1552. PMID: 18420096, DOI: 10.1016/j.jacc.2008.01.020.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicChromium AlloysClopidogrelCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisDiabetes MellitusFemaleHumansMaleMiddle AgedPaclitaxelPlatelet Aggregation InhibitorsPolymersRiskThromboembolismTiclopidineTime FactorsConceptsPercutaneous coronary interventionTarget vessel revascularizationDrug-eluting stentsMajor adverse cardiac eventsMultivessel percutaneous coronary interventionTaxus drug-eluting stentsMyocardial infarctionAdjudicated deathAdverse cardiac eventsPrimary end pointSegment late lossSingle target lesionPre-specified subgroupsStent thrombosis ratesTreatment of SingleVessel revascularizationCardiac eventsCoronary interventionII studyThrombosis rateAngiographic analysisEpicardial vesselsTarget lesionsLate lossPatients
2005
Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction—The smoker's paradox revisited
Weisz G, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey TD, Rutherford BD, Mehran R, Aymong E, Lansky A, Grines CL, Stone GW. Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction—The smoker's paradox revisited. American Heart Journal 2005, 150: 358-364. PMID: 16086943, DOI: 10.1016/j.ahj.2004.01.032.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAnticoagulantsComorbidityCoronary AngiographyFemaleFollow-Up StudiesHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMortalityMyocardial InfarctionPlatelet Aggregation InhibitorsProspective StudiesRecurrenceRiskSmokingSmoking CessationStentsStrokeSurvival AnalysisTreatment OutcomeConceptsAcute myocardial infarctionSmoking statusCurrent smokersSmoker's paradoxCoronary interventionFormer smokersCigarette smokingMyocardial infarctionPrior acute myocardial infarctionPrimary percutaneous coronary interventionPercutaneous transluminal coronary angioplastyTriple-vessel coronary diseaseMechanical reperfusion therapyPrimary coronary interventionProcedural success ratePercutaneous coronary interventionTransluminal coronary angioplastyAge-adjusted riskCurrent smoking statusOccurrence of AMITime of presentationLower mortality rateCADILLAC trialLate mortalityPrimary PCI
2003
Comparison of effect of glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions on risk of hemorrhagic stroke in patients ≥75 years of age versus those <75 years of age
Iakovou I, Dangas G, Mehran R, Mintz GS, Lansky AJ, Aymong ED, Nikolsky E, Vagaonescu T, Glasser LA, Stone GW, Leon MB, Moses JW. Comparison of effect of glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions on risk of hemorrhagic stroke in patients ≥75 years of age versus those <75 years of age. The American Journal Of Cardiology 2003, 92: 1083-1086. PMID: 14583360, DOI: 10.1016/j.amjcard.2003.07.007.Peer-Reviewed Original Research